First-in-human phase 0 study of ¹¹¹In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging.

ABSTRACT:

Introduction

Tumors over-expressing the human epithelial receptor 2 (HER2) or exhibiting amplification or mutation of its proto-oncogene have a poorer prognosis. Using trastuzumab and/or other HER2 targeted therapies can increase overall survival in patients with HER2(+) tumors making it critical to accurately identify patients who may benefit. We report on a Phase 0 study of the imaging agent, ¹¹¹In-CHX-A"-DTPA trastuzumab, in patients with known HER2 status to evaluate its safety and biodistribution and to obtain preliminary data regarding its ability to provide an accurate, whole-body, non-invasive means to determine HER2 status.

Methods

¹¹¹In-CHX-A"-DTPA trastuzumab was radiolabeled on-site and slowly infused into 11 patients who underwent single (n

SUBMITTER: Kurdziel KA 

PROVIDER: S-EPMC6425962 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature